Meet the Classes of Directly Acting Antiviral Agents: Strengths and Weaknesses

Kristina R Chacko; Paul J Gaglio

doi:10.1016/j.cld.2015.06.002

Meet the Classes of Directly Acting Antiviral Agents: Strengths and Weaknesses

Clin Liver Dis. 2015 Nov;19(4):605-17, v. doi: 10.1016/j.cld.2015.06.002. Epub 2015 Jul 26.

Authors

Kristina R Chacko¹, Paul J Gaglio²

Affiliations

¹ Division of Hepatology, Department of Medicine, Montefiore Einstein Liver Center, Montefiore Medical Center, Albert Einstein College of Medicine, 111 East 210 Street Rosenthal 2 Red Zone, Bronx, NY 10467, USA.
² Division of Hepatology, Department of Medicine, Montefiore Einstein Liver Center, Montefiore Medical Center, Albert Einstein College of Medicine, 111 East 210 Street Rosenthal 2 Red Zone, Bronx, NY 10467, USA. Electronic address: [email protected].

PMID: 26466650
DOI: 10.1016/j.cld.2015.06.002

Abstract

This article discusses direct-acting antiviral agents that target hepatitis C virus replication, their mechanism of action, strengths, and weaknesses. In addition, varying strategies using combinations of these agents are discussed.

Keywords: Direct-acting antiviral agents; NS5A inhibitors; Polymerase inhibitors; Protease inhibitors.

Publication types

Review

MeSH terms

Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use*
Drug Therapy, Combination
Hepacivirus / drug effects*
Hepacivirus / genetics
Hepacivirus / physiology
Hepatitis C / drug therapy*
Humans
Nucleic Acid Synthesis Inhibitors / pharmacology
Nucleic Acid Synthesis Inhibitors / therapeutic use*
Polymorphism, Genetic
Protease Inhibitors / pharmacology
Protease Inhibitors / therapeutic use*
RNA, Viral / biosynthesis
Viral Nonstructural Proteins / antagonists & inhibitors
Virus Internalization / drug effects
Virus Replication / drug effects*

Substances

Antiviral Agents
Nucleic Acid Synthesis Inhibitors
Protease Inhibitors
RNA, Viral
Viral Nonstructural Proteins
NS-5 protein, hepatitis C virus